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Effects of empagliflozin on blood pressure and markers of arterial
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Aims: To determine the effects of empagliflozin on blood pressure (BP) and markers of arterial stiffness and vascular resistance in patients with type 2
diabetes mellitus (T2DM).
Methods: We conducted a post hoc analysis of data from a phase III trial in patients with T2DM and hypertension receiving 12weeks’ empagliflozin
and four phase III trials in patients with T2DM receiving 24weeks’ empagliflozin (cohort 1, n= 823; cohort 2, n= 2477). BP was measured using 24-h BP
monitoring (cohort 1) or seated office measurements (cohort 2).
Results: Empagliflozin reduced systolic BP (SBP) and diastolic BP in both cohorts (p< 0.001 vs placebo), without increasing heart rate. Empagliflozin
reduced pulse pressure (PP; adjusted mean difference vs placebo cohort 1: −2.3 mmHg; cohort 2: −2.3 mmHg), mean arterial pressure (MAP; cohort 1,
−2.3 mmHg; cohort 2,−2.1 mmHg) and double product (cohort 1,−385 mmHg× bpm; cohort 2,−369 mmHg× bpm) all p< 0.001 vs placebo. There was
a trend towards a reduction in the ambulatory arterial stiffness index (AASI) with empagliflozin in cohort 1 (p= 0.059 vs placebo). AASI was not measured
in cohort 2. Subgroup analyses showed that there were greater reductions in PP with increasing baseline SBP in cohort 1 (p= 0.092). In cohort 2, greater
reductions in MAP were achieved in patients with higher baseline SBP (p= 0.027) and greater reductions in PP were observed in older patients (p= 0.011).
Conclusions: Empagliflozin reduced BP and had favourable effects on markers of arterial stiffness and vascular resistance.
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Introduction
Cardiovascular (CV) disease is the major cause of morbidity
and mortality in patients with type 2 diabetes (T2DM) [1]. The
risk of CV disease in adults with diabetes is double that in
adults without diabetes, and diabetes is estimated to account for
10–12% of all vascular deaths [2]. Patients with T2DM often
have numerous CV risk factors and a multifactorial approach
to addressing CV risk, including controlling glycaemia, blood
pressure (BP) and body weight, is recommended in these
patients [1,3].
The metabolic abnormalities that are characteristic of dia-
betes, such as hyperglycaemia, excess free fatty acids and insulin
resistance, can lead to suppression of nitric oxide produc-
tion and activation of the renin-angiotensin system, leading to
oxidative stress, endothelial dysfunction and activation of the
receptor for advanced glycation end products (RAGE) [4–6].
These may contribute to hypertension [7] or to increased arte-
rial stiffness related to vascular calcification or accumulation of
Correspondence to: Odd Erik Johansen, Boehringer Ingelheim Norway KS, Asker, Norway.
E-mail: odd_erik.johansen@boehringer-ingelheim.com
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial
purposes.
collagen [8,9] that could partly explain the increased risk of vas-
cular complications associated with T2DM [4].
Arterial stiffness is a strong predictor of CV events, heart fail-
ure and death [10–12]. Although aortic pulse wave velocity is
generally considered to be the ‘gold standard’ for non-invasive
assessments of arterial stiffness, in clinical practice, pulse
pressure (PP) can be used as a surrogate marker. PP is deter-
mined by cardiac output and the stiffness of elastic central
arteries, such as the aorta, and may be calculated as the differ-
ence between systolic BP (SBP) and diastolic BP (DBP) [13].
Increased peripheral PP is an independent predictor of CV
disease in patients with T2DM [14–16], and a meta-analysis
showed that the relative risks of CV events were similar for an
increase in central SBP and central PP to those for their periph-
eral (brachial) counterparts [17]. Another marker of arterial
stiffness is the ambulatory arterial stiffness index [AASI: 1
minus the regression slope of DBP and SBP values derived
from 24-h ambulatory BPmonitoring (ABPM) [18]].TheAASI
represents the dynamic relationship between SBP and DBP,
as defined by haemodynamic arterio-ventricular properties,
and has been reported to be an independent predictor of CV
mortality [19].
Mean arterial pressure (MAP) is a measure of central
haemodynamics that reflects the cardiac cycle and is deter-
mined by cardiac output, systemic vascular resistance and
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central venous pressure. MAP is calculated as 2/3 DBP+ 1/3
SBP [16] and has been shown to be predictive of CV events in
patients with T2DM.
The myocardium’s workload is related to vascular stiffness
and cardiac function, and one variable that quantifies this is the
double product (DP), also known as the rate pressure product
(RPP). This is calculated as heart rate× SBP and provides an
indirectmeasure ofmyocardial oxygen demand. Chronic eleva-
tions of DP, representing an increased cardiac load, may cause
long-term cardiac impairment and DP is associated with CV
complications, CV mortality and non-CV mortality [20,21].
Empagliflozin is a potent and selective sodium glucose
cotransporter 2 (SGLT2) inhibitor [22] used in the treat-
ment of T2DM. In phase III trials, empagliflozin (10 and
25mg) improved glycaemic control with a low risk of hypo-
glycaemia, and was associated with reductions in BP and body
weight [23–27]. In a 4-week study in patients with T2DM,
empagliflozin monotherapy reduced oxidative stress, as shown
by reductions in 8-iso-prostaglandin2𝛼, and also improved
daily blood glucose control [28]. Empagliflozin has been shown
to have central haemodynamic effects: in patients with type
1 diabetes (T1DM), empagliflozin reduced arterial stiffness
assessed by measurement of carotid-radial pulse wave velocity
and radial, carotid and aortic augmentation indices [29].
To determine the effects of empagliflozin on markers of
arterial stiffness (PP and AASI) and arterial resistance (MAP)
in patients with T2DM, we analysed data from five phase III
studies. We also determined the effects of empagliflozin on
indirect determinants ofmyocardial oxygen demand and hence
the workload on the heart (heart rate, BP and DP). Further,
we conducted subgroup analyses to test our hypothesis that
empagliflozin would reduce BP, PP andMAP across subgroups
defined by age, sex and degree of hypertension at baseline, with
greater reductions in older patients and those with the highest
SBP at baseline.
Methods
Study Design and Patients
Data from two cohorts of patients, one treated with
empagliflozin for 12weeks (cohort 1) and one treated
with empagliflozin for 24weeks (cohort 2), were analysed.
Cohort 1 comprised patients from the EMPA-REG BP™ trial
[27]. Patients had T2DM with hypertension (mean seated
office SBP 130–159mmHg and DBP 80–99mmHg), glycated
haemoglobin (HbA1c)≥7 and≤10% (≥53 and≤86mmol/mol)
and a body mass index ≤45 kg/m2 at baseline. Patients were
either drug-naive [had not received any oral glucose-lowering
therapy, glucagon-like peptide-1 (GLP-1) analogue, or insulin
for ≥12weeks (≥16weeks for pioglitazone) before randomiza-
tion] or had been receiving stable doses of glucose-lowering
therapy [oral agents or GLP-1 analogue at doses unchanged
for ≥12weeks (≥16weeks for pioglitazone) before random-
ization, or insulin at dose changed by ≤10% for ≥12weeks
before randomization] [27]. Patients were required to have
been receiving no, one or two BP-lowering medications at a
stable dose for ≥4weeks at screening and throughout a 2-week
placebo run-in period. Patients were randomized to receive
empagliflozin 10mg, empagliflozin 25mg, or placebo once
daily for 12weeks. Patients underwent 24-h ABPM ≤7 days
before randomization and at week 12 [27]. During the treat-
ment period, patients continued their background BP-lowering
therapy at an unchanged dose, but changes in BP-lowering
medication could be initiated if a patient had a mean SBP
≥160mmHg and/or a mean DBP ≥100mmHg at a clinic visit.
Cohort 2 comprised patients from the four pivotal trials
of empagliflozin required for regulatory submissions: EMPA-
REG MONO™ [23], EMPA-REG MET™ [24], EMPA-REG
METSU™ [25] and EMPA-REG PIO™ [26]. Patients in
these trials had T2DM, HbA1c ≥7 and ≤10% (≥53 and
≤86mmol/mol) and a body mass index ≤45 kg/m2. Patients
in the EMPA-REG MONO™ trial were drug-naive (had
not received glucose-lowering therapy for ≥12weeks before
randomization) [23]. Patients in the EMPA-REG MET™ or
EMPA-REG METSU™ trials had received immediate-release
metformin [≥1500mg/day, up to maximum tolerated
dose (MTD) or maximum dose according to local label]
unchanged for ≥12weeks before randomization, or met-
formin plus a sulphonylurea (≥50% of MTD, up to the MTD
or maximum dose according to local label) unchanged for
≥12weeks before randomization, respectively [24,25]. Patients
in the EMPA-REG PIO™ trial had received pioglitazone
(≥30mg/day, up to MTD or maximum dose according to
local label) unchanged for ≥12weeks before randomization,
with or without metformin immediate release (as described
above) [26]. In all four trials, patients were randomized
to receive empagliflozin 10mg, empagliflozin 25mg, or
placebo as monotherapy (EMPA-REGMONO™) or add-on to
background therapy for 24weeks.
Glucose-lowering rescue medication could be initiated at
the discretion of the investigator if, after an overnight fast, a
patient had a confirmed plasma glucose level >13.3mmol/l
during the first 12weeks of treatment or, in the 24-week tri-
als, >11.1mmol/l [or HbA1c >8.5% (69mmol/mol) in the
EMPA-REG MET™ and EMPA-REG METSU™ studies] dur-
ing weeks 12–24.
All studies were approved by the Institutional Review Boards
and Independent Ethics Committees and Competent Authori-
ties of the participating centres and complied with the Decla-
ration of Helsinki in accordance with the International Con-
ference onHarmonisationHarmonised Tripartite Guideline for
Good Clinical Practice. All patients who participated in these
studies provided written informed consent.
Endpoints and Measurements
In the present post hoc analysis, the following endpoints were
analysed in cohort 1: changes from baseline in HbA1c and
in 24-h SBP and DBP, heart rate, PP, MAP, DP (or RPP) and
AASI (based on 24-h ABPM measurements) at week 12. The
following endpoints were analysed in cohort 2: changes from
baseline in HbA1c, seated office SBP and DBP, heart rate, PP,
MAP and DP (or RPP) at week 24.
In both cohorts, changes from baseline in SBP, DBP, PP
and MAP were analysed in subgroups of patients by baseline
age (<50, 50 to <65, 65 to <75, ≥75 years), sex, and baseline
SBP (<130, 130–140, >140mmHg). PP was calculated as
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SBP – DBP (mmHg). MAP was calculated as 2/3 DBP+ 1/3
SBP (mmHg). DP (or RPP) was calculated as heart rate
(bpm)× SBP (mmHg). AASI was calculated as 1 minus the
regression slope of DBP on SBP during 24-h ABPM.
In light of the small/modest differences in the impact of
empagliflozin 10 and 25mg on reducing SBP andDBP [23–27],
the two doses were pooled for the purpose of the present
analyses.
Statistical Analyses
For each cohort, data from patients in the empagliflozin 10mg
and empagliflozin 25mg groups were pooled. Changes from
baseline in each cohort were analysed using an analysis of
covariance (ancova) with baseline HbA1c and the baseline
value of the endpoint in question (if not HbA1c) as linear
covariates, and baseline estimated glomerular filtration rate
(Modification of Diet in Renal Disease equation), region and
treatment as fixed effects. The number of BP-lowering medica-
tions at baseline was an additional fixed effect in analysis of data
from cohort 1. In cohort 2, the individual study was an addi-
tional fixed effect when analysing the data. Changes from base-
line in SBP, DBP, PP andMAP in subgroups of baseline age, sex
and baseline SBP were analysed using the same ancovamodel,
but including baseline age, sex and baseline SBP, respectively, as
additional linear covariates and the corresponding treatment by
subgroup of interest interaction. For cohort 1, baseline SBP was
the baseline mean 24-h SBP value. Analyses were conducted on
the full analysis set (FAS). For cohort 1, the FAS comprised ran-
domized patients who received ≥1 dose of study drug and had
a baseline HbA1c value and a baseline mean 24-h SBP value.
For cohort 2, the FAS comprised randomized patients who
received≥1 dose of study drug and had a baselineHbA1c value.
Values observed after initiation of glucose-lowering rescue
therapy were set to missing. A last observation carried forward
(LOCF) approach was used to impute missing data. Statistical
analyses were performed using % data for HbA1c.
Results
Patients
Of 825 patients randomized in the EMPA-REG BP™ trial, 823
were included in the FAS for cohort 1 (empagliflozin: n= 552;
placebo: n= 271). Of the 2482 patients randomized in the four
24-week phase III trials, 2477 patients were included in the FAS
for cohort 2 (empagliflozin: n= 1652; placebo: n= 825). In each
cohort, patient demographics and baseline characteristics were
generally balanced between treatment groups (Table S1).
Glycaemic Control
In both cohorts, empagliflozin significantly reduced HbA1c
from baseline compared with placebo. In cohort 1, the
adjusted mean± standard error (s.e.) change from baseline in
HbA1c at week 12 was 0.03 (± 0.04)% [0.3 (± 0.4)mmol/
mol] with placebo compared with −0.61 (± 0.02)%
[−6.7 (± 0.3)mmol/mol] with empagliflozin {adjusted mean
difference vs placebo: −0.64% [95% confidence interval
(CI) −0.72, −0.55] or −7.0mmol/mol (95% CI −7.9, −6.0);
p< 0.001}. In cohort 2, the adjusted mean (± s.e.) change
from baseline in HbA1c at week 24 was −0.08 (± 0.03)%
[−0.9 (± 0.3) mmol/mol] with placebo compared with
−0.73 (± 0.02)% [−8.0 (± 0.2) mmol/mol] with empagliflozin
[adjusted mean difference vs placebo: −0.65% (95% CI −0.71,
−0.59) or −7.1mmol/mol (95% CI −7.8, −6.4); p< 0.001].
The proportions of patients with imputed data for change
from baseline in HbA1c in cohort 1 at week 12 were 10.3
and 9.6% for patients treated with empagliflozin and placebo,
respectively, whereas in cohort 2, the corresponding figures at
week 24 were 12.2 and 25.7%.
Blood Pressure and Heart Rate
In both cohorts, empagliflozin significantly reduced SBP and
DBP from baseline compared with placebo. In cohort 1, the
adjusted mean difference versus placebo in change from base-
line in mean 24-h SBP at week 12 was −3.9mmHg (95% CI
−5.0, −2.7; p< 0.001) and in mean 24-h DBP was −1.5mmHg
(95% CI −2.2, −0.8; p< 0.001; Figure S1). In cohort 2, the
adjusted mean difference versus placebo in change from base-
line in SBP at week 24 was −3.6mmHg (95% CI −4.5, −2.7;
p< 0.001) and in DBP was −1.3mmHg (95% CI −1.9, −0.8;
p< 0.001; Figure S1). The adjusted mean difference versus
placebo in change from baseline in mean 24-h heart rate
was −0.6 bpm (95% CI −1.4, 0.3; p= 0.209) in cohort 1 and
−0.8 bpm (95% CI −1.4, −0.2; p= 0.012) in cohort 2 (Figure
S1). The proportions of patients with imputed data for change
frombaseline in SBP in cohort 1 at week 12were 12.7 and 13.3%
for patients treated with empagliflozin and placebo, respec-
tively, whereas in cohort 2, the corresponding figures at week
24 were 11.6 and 25.1%.
Markers of Arterial Stiffness and Vascular Resistance
Empagliflozin significantly (p< 0.001) reduced PP, MAP and
DP (or RPP) compared with placebo in both cohorts (Figure 1).
In cohort 1, the reduction in AASI did not reach significance
(p= 0.059 for differences vs placebo).
Subgroup Analyses: Baseline Age. With increasing age, baseline
SBP generally increased and baseline DBP generally decreased,
hence baseline PP increased (Figure 2). Empagliflozin reduced
SBP, DBP, PP and MAP compared with placebo in most sub-
groups by baseline age; however, none of the interaction p
values reached significance (p< 0.1) except for PP in cohort
2, which was reduced to a greater extent in older patients
(p= 0.011; Table 1).
Subgroup Analyses: Sex. In cohort 1, baseline SBP and DBP
were higher in men than women (Figure 3). In cohort 2,
baseline SBP was higher in men than women (Figure 3).
Empagliflozin significantly reduced SBP, DBP, PP and MAP
compared with placebo in both sexes (Table 1; Figure 3),
with no significant interactions between sex and treatment
responses.
Subgroup Analyses: Baseline SBP. Baseline DBP, PP and
MAP increased with baseline SBP and empagliflozin
significantly reduced SBP compared with placebo in all
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Figure 1. Changes in markers of arterial stiffness and vascular resistance. (A) Change from baseline in pulse pressure (PP) at week 12 in cohort 1 and week
24 in cohort 2 [analysis of covariance (ANCOVA) using last observation carried forward (LOCF)]. (B) Change from baseline in mean arterial pressure (MAP)
at week 12 in cohort 1 and week 24 in cohort 2 (ANCOVA, LOCF). (C) Change from baseline in double product (DP) or rate pressure product (RPP) at week
12 in cohort 1 and week 24 in cohort 2 (ANCOVA, LOCF). (D) Change from baseline in ambulatory arterial stiffness index (AASI) at week 12 in cohort 1.
Data are adjusted mean± standard error (s.e.) in the full analysis set. In cohort 1, measurements were based on mean 24-h ABPM and in cohort 2, they
were based on seated office measurements.
subgroups (Figure 4), with significant treatment by baseline
SBP interaction in cohort 2 (p= 0.013; Table 1; Figure 4).
Empagliflozin also significantly reduced DBP, PP and MAP in
all baseline SBP subgroups, except for DBP in patients with
baseline SBP>140mmHg in cohort 1 (Table 1; Figure 4).There
appeared to be greater reductions in PPwith increasing baseline
SBP in both cohorts, although the treatment by baseline SBP
interaction only reached significance in cohort 1 (p= 0.092 for
treatment by baseline SBP interaction; Table 1). In cohort 2,
there were greater reductions in MAP with increasing baseline
SBP (p= 0.027 for treatment by baseline SBP interaction;
Table 1).
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Safety and Tolerability
Data on the safety and tolerability of empagliflozin, including
adverse events and changes in lipids and other laboratory
variables, have been published for the individual trials [23–27].
In brief, empagliflozin was associated with an incidence of
hypoglycaemia similar to placebo except when used in
combination with a sulphonylurea. Events consistent with
genital infection were reported in a higher proportion of
patients receiving empagliflozin than placebo, while events
consistent with urinary tract infection were reported by
a similar proportion of patients receiving empagliflozin and
placebo. Events consistentwith volume depletionwere reported
in 1 patient (0.4%) on placebo and 1 patient on empagliflozin
(0.2%) in cohort 1, and 2 patients (0.2%) on placebo and 5
patients (0.3%) on empagliflozin in cohort 2; none of these
events was reported in patients aged ≥75 years. Increases
in HDL cholesterol with empagliflozin versus placebo were
reported in four of the five studies [23–26], and two studies
reported increases in LDL cholesterol with empagliflozin versus
placebo [24,27].
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Figure 2. Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP) and mean arterial pressure (MAP) by subgroups of baseline
age. (A) SBP, DBP, PP and MAP at baseline and at week 12 in cohort 1. (B) SBP, DBP, PP and MAP at baseline at week 24 in cohort 2. Baseline data
are mean± standard error (s.e.), week 12 or 24 data are adjusted mean± s.e. based on analysis of covariance (ANCOVA) in the full analysis set using last
observation carried forward (LOCF) imputation. In cohort 1, measurements were based on mean 24-h ambulatory blood pressure monitoring (ABPM)
and in cohort 2, they were based on seated office measurements. ***p< 0.001, **p< 0.01 and *p< 0.05 for adjusted mean differences for empagliflozin
versus placebo in change from baseline based on ANCOVA with LOCF imputation.
Discussion
The objective of the present post hoc analysis was to explore
the effects of empagliflozin on BP, arterial stiffness and vascular
resistance in patients with T2DM. In both of the cohorts stud-
ied, empagliflozin reduced BP, without increasing heart rate,
and had favourable effects on markers of arterial stiffness and
vascular resistance as well as on a marker of myocardial work-
load.
The differences in baseline SBP, DBP and PP with increasing
age were, as expected, based on population data. After the
age of 50 years, SBP continues to increase, while DBP tends
to remain fairly stable between ages 50 and 60 years and
then decrease, leading to a widening PP [30]. These changes
suggest that large artery stiffness becomes the predominant
haemodynamic factor driving increases in SBP in individuals
aged>60 years, while peripheral vascular resistance drives BP
in younger individuals [30].
As we hypothesized, the greatest reductions in PP were
observed in the oldest patients and in those with the highest
SBP at baseline. MAP was reduced in all the subgroups, with
no greater reduction in patients with higher age or SBP at base-
line. This is explained by the dominance of DBP in the mea-
surement of MAP, which means that MAP reflects small artery
resistance and cardiac output to a greater extent than PP. It
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appears, therefore, that empagliflozin is efficacious across the
entire age range but its effects may differ with age; for example,
in younger patients, BP reduction may be mediated via effects
on small artery resistance and, in the elderly, largely via effects
on large artery stiffness. The reduction in the DP (or RPP), a
marker of cardiac workload, observed with empagliflozin was
driven by reduction in SBP; empagliflozin had a neutral effect
on heart rate in this analysis, consistent with the results of pre-
vious trials in patients with T2DM and with the results of a
study on the effects of empagliflozin on heart rate variability
in patients with T1DM [29]. The reduction in the DP (or RPP)
is intriguing from the perspective of its prognostic impact on
CV and total mortality, but also from a congestive heart failure
perspective, and it is tempting to speculate that empagliflozin
may reduce hospitalization for heart failure. Interestingly, in a
16-week study in a diabetic hypertensive rat model of heart fail-
ure, empagliflozin was observed to have beneficial effects on
cardiac morphology and function [31].
The observation that empagliflozin has an impact on the
vasculature without increasing pulse rate is interesting from a
CV perspective and could be interpreted as a consequence of
a relative reduction in the sympathetic nervous system tonus.
Although neurohormonal factors could also play a role, this
notion is supported by mechanistic data from normotensive
patients with T2DM in whom no apparent changes in muscle
sympathetic nerve activity, measured using microneurography,
were observed, despite clinical benefits with regard to BP and
weight [32].
Reductions in SBP andDBP have consistently been observed
with the use of SGLT2 inhibitors in patients with T2DM
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Table 1. Subgroup analyses of differences between empagliflozin and placebo in changes from baseline in markers of arterial stiffness and vascular
resistance.
Placebo Empagliflozin
Adjusted mean (95% CI) differences for empagliflozin
vs placebo in change from baseline in:
Subgroup n n SBP, mmHg DBP, mmHg PP, mmHg MAP, mmHg
Cohort 1
Baseline age
<50 years 31 65 −3.5 (−7.0, −0.0) −1.6 (−3.6, 0.4) −1.8 (−4.0, 0.4) −2.3 (−4.6, 0.1)
p value <0.050 0.111 0.105 0.063
50 to <65 years 154 313 −4.3 (−5.8, −2.7) −1.7 (−2.6, −0.8) −2.4 (−3.4, −1.5) −2.6 (−3.7, −1.5)
p value <0.001 <0.001 <0.001 <0.001
65 to <75 years 79 136 −3.1 (−5.4, −0.9) −1.2 (−2.5, 0.1) −2.0 (−3.4. −0.6) −1.9 (−3.4, −0.3)
p value 0.006 0.073 0.006 0.018
≥75 years 7 38 −4.4 (−11.0, 2.2) −0.6 (−4.4, 3.2) −4.4 (−8.5, −0.4) −1.7 (−6.2, 2.8)
p value 0.189 0.748 0.033 0.462
Interaction p value 0.865 0.874 0.665 0.881
Sex
Male 168 327 −3.7 (−5.2, −2.1) −1.3 (−2.1, −0.4) −2.3 (−3.3, −1.4) −2.1 (−3.1, −1.0)
p value <0.001 0.005 <0.001 <0.001
Female 103 225 −4.2 (−6.0, −2.3) −1.9 (−3.0, −0.8) −2.2 (−3.4, −1.0) −2.7 (−4.0, −1.4)
p value <0.001 <0.001 <0.001 <0.001
Interaction p value 0.681 0.379 0.875 0.461
Baseline SBP
SBP<130mmHg 130 276 −2.4 (−4.1, −0.7) −1.1 (−2.1, −0.1) −1.4 (−2.5, −0.4) −1.7 (−2.8, −0.5)
p value 0.006 0.024 0.007 0.005
SBP 130–140mmHg 85 147 −4.9 (−7.1, −2.7) −2.1 (−3.3, −0.8) −2.9 (−4.2, −1.5) −3.0 (−4.5, −1.6)
p value <0.001 0.001 <0.001 <0.001
SBP >140mmHg 56 129 −4.6 (−7.3, −2.0) −1.4 (−2.9, 0.1) −3.2 (−4.8, −1.7) −2.5 (−4.2, −0.7)
p value <0.001 0.059 <0.001 0.005
Interaction p value 0.153 0.494 0.092 0.342
Cohort 2
Baseline age
<50 years 222 464 −3.3 (−5.0, −1.5) −1.1 (−2.2, 0.0) −2.2 (−3.5, −0.8) −1.8 (−3.0, −0.6)
p value <0.001 0.053 0.002 0.003
50 to <65 years 459 871 −3.4 (−4.6, −2.2) −1.8 (−2.6, −1.0) −1.6 (−2.6, −0.6) −2.3 (−3.2, −1.5)
p value <0.001 <0.001 0.001 <0.001
65 to <75 years 119 276 −4.0 (−6.3, −1.6) −0.3 (−1.8, 1.1) −3.6 (−5.5. −1.8) −1.6 (−3.2, 0.0)
p value 0.001 0.649 <0.001 0.053
≥75 years 25 41 −8.3 (−13.7, −2.9) −0.1 (−3.5, 3.3) −8.2 (−12.4, −3.9) −2.8 (−6.5, 0.9)
p value 0.003 0.955 <0.001 0.135
Interaction p value 0.365 0.284 0.011 0.788
Sex
Male 424 927 −3.8 (−5.1, −2.6) −1.5 (−2.3, −0.7) −2.3 (−3.3, −1.3) −2.3 (−3.2, −1.5)
p value <0.001 <0.001 <0.001 <0.001
Female 401 725 −3.4 (−4.7, −2.0) −1.2 (−2.0, −0.3) −2.2 (−3.2, −1.1) −1.9 (−2.8, −1.0)
p value <0.001 0.006 <0.001 <0.001
Interaction p value 0.598 0.546 0.851 0.526
Baseline SBP
SBP<130mmHg 462 891 −2.6 (−3.9, −1.3) −0.8 (−1.6, −0.1) −1.7 (−2.7, −0.7) −1.4 (−2.2, −0.6)
p value <0.001 0.033 <0.001 0.001
SBP 130–140mmHg 201 412 −4.0 (−5.9, −2.1) −1.7 (−2.8, −0.5) −2.4 (−3.9, −0.9) −2.5 (−3.7, −1.2)
p value <0.001 0.005 0.001 <0.001
SBP >140mmHg 162 349 −6.3 (−8.4, −4.2) −2.3 (−3.6, −1.1) −3.6 (−5.3, −2.0) −3.5 (−4.9, −2.2)
p value <0.001 <0.001 <0.001 <0.001
Interaction p value 0.013 0.123 0.124 0.027
CI, confidence interval; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; SBP, systolic blood pressure.
Data are adjusted mean (95% CI) using analysis of covariance (ANCOVA) with LOCF imputation in randomized patients who received ≥1 dose of study
medication and had a baseline Glycated haemoglobin value (both cohorts) and baseline mean 24-h SBP value (cohort 1 only). Measurements were based
on mean 24-h ABPM in cohort 1 and seated office measurements in cohort 2. Data after initiation of glucose-lowering rescue therapy were set to missing.
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Figure 3. Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP) and mean arterial pressure (MAP) by sex. (A) SBP, DBP, PP
and MAP at baseline and at week 12 in cohort 1. (B) SBP, DBP, PP and MAP at baseline and at week 24 in cohort 2. Baseline data are mean± standard
error (s.e.), week 12 or 24 data are adjusted mean± s.e. based on analysis of covariance (ANCOVA) in the full analysis set using last observation carried
forward (LOCF) imputation. In cohort 1, measurements were based on mean 24-h ambulatory blood pressure monitoring (ABPM) and in cohort 2, they
were based on seated office measurements. ***p< 0.001, **p< 0.01 and *p< 0.05 for adjusted mean differences for empagliflozin versus placebo in change
from baseline based on ANCOVA with LOCF imputation.
[33], but no data in humans have been published on reduc-
tions in arterial stiffness or vascular resistance with SGLT2
inhibitors other than empagliflozin. As no other classes of
glucose-lowering drugs, including dipeptidyl peptidase-4
inhibitors and GLP-1 receptor analogues, have shown simi-
lar findings, the observed improvements in arterial stiffness
and vascular resistance could be a unique phenomenon
for empagliflozin, which could have major implications for
vascular health and CV prognosis.
The mechanisms by which empagliflozin reduces BP and
arterial stiffness are not fully understood, but may be related
to improved glycaemic control, weight loss, volume contrac-
tion as a result of osmotic diuresis or reduced oxidative stress
[29,33–36]. In a rat model, empagliflozin was further shown to
normalize endothelial function, reduce oxidative stress in aor-
tic vessels, reverse a pro-inflammatory phenotype, and improve
AGE/RAGE signalling [37], all pathways of potential impor-
tance to a reduction in arterial stiffness [36]. In addition, in a
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mouse model of obesity and T2DM, empagliflozin ameliorated
pericoronary arterial fibrosis, coronary arterial thickening and
cardiac macrophage infiltration, effects that are associated with
attenuation of oxidative stress in CV tissue [38].
In this analysis, events consistent with volume depletion
were rare and no such events were reported in patients aged
≥75 years; however, the potential for volume depletion in
vulnerable patients such as the elderly, those with renal
impairment, those with low SBP and those receiving diuretics
is acknowledged in the prescribing information for SGLT2
inhibitors [39–41] and appropriate caution should be exercised
in the use of empagliflozin in such patients in clinical practice.
Strengths of the analyses presented in this manuscript
include the large number of patients analysed (cohort 2) and
the use of 24-h ABPM in patients with hypertension (cohort
1). Limitations include the post hoc nature of the analyses, the
relatively small number of patients in the older age groups, that
the analyses did not account for multiple testing, and the short
exposure period to the drug (12 or 24weeks). In addition, there
were few Asian patients with advanced hypertension, which
limits the generalizability of our findings to this population.
Indirect evidence suggests that reductions in arterial stiff-
ness and vascular resistance may reduce CV risk beyond BP
reduction [42,43]. Reductions in BP and arterial stiffness are
two of the effects of SGLT2 inhibitors that might ameliorate
CV risk and heart failure in patients with T2DM [44]. The
effects of empagliflozin on CV and microvascular outcomes
are being investigated in the EMPA-REG OUTCOME® trial
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Figure 4. Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP) and mean arterial pressure (MAP) by subgroups of baseline
SBP. (A) SBP, DBP, PP and MAP at baseline and at week 12 in cohort 1. (B) SBP, DBP, PP and MAP at baseline and at week 24 in cohort 2. Baseline
data are mean± standard error (s.e.), week 12 or 24 data are adjusted mean± s.e. based on analysis of covariance (ANCOVA) in the full analysis set using last
observation carried forward (LOCF) imputation. In cohort 1, measurements were based onmean 24-h ambulatory blood pressure monitoring (ABPM) and
in cohort 2, they were based on seated office measurements. ***p< 0.001, **p< 0.01 and *p< 0.05 for adjusted mean differences for empagliflozin versus
placebo in change from baseline based on ANCOVA with LOCF imputation.
(NCT01131676) [45], which will report results in the second
half of 2015.
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